Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9208-9218

  Johnson, Peter W M ^a   Radford, John A ^b   Cullen, Michael H ^b   Sydes, Matthew R ^b   Walewski, Jan ^b   Jack, Andrew S ^b   MacLennan, Kenneth A ^b   Stenning, Sally P ^b   Clawson, Simon ^b   Smith, Paul ^b   Ryder, David ^b   Hancock, Barry W ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT; CHLVPP PROTOCOL; PABLOE PROTOCOL;

ACUTE LEUKEMIA; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CELL HETEROGENEITY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; HODGKIN DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; DISEASE COURSE; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHLORAMBUCIL; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PROCARBAZINE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 33644818361     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.2151     Document Type: Article

References (20)

1. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
2. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
3. Cullen MH, Stuart NS, Woodroffe C, et al: ChlVPP/PABIOE and radiotherapy in advanced Hodgkin's disease: The Central Lymphoma Group. J Clin Oncol 12:779-787, 1994
4. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
5. Hancock BW, Vaughan-Hudson G, Vaughan-Hudson B, et al: LOPP alternating with EVAP is superior to LOPP alone in the initial. J Clin Oncol 10:1252-1258, 1992
6. Somers R, Carde M, Henry-Amar M, et al: A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organisation for Research and Treatment of Cancer lymphoma cooperative group and groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279-287, 1994
7. Radford JA, Crowther D, Rohatiner AZ, et al: Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 13:2379-2385, 1995
8. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421-1430, 1996
9. Connors JM, Klimo P, Adams G, et al: Treatment of advanced Hodgkin's disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD-A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:1638-1645, 1997
10. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
11. Donaldson SS, Hancock SL, Hoppe RT: The Janeway lecture: Hodgkin's disease-Finding the balance between cure and late effects. Cancer J Sci Am 5:325-333, 1999
12. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993
13. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993
14. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
15. Radford JA, Rohatiner AZ, Ryder WD, et al: ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20:2988-2994, 2002
16. Clark ST, Radford JA, Crowther D, et al: Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 13:134-139, 1995
17. Hancock BW, Gregory WM, Cullen MH, et al: ChlPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer 84:1293-1300, 2001
18. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of Hodgkin's Disease. J Clin Oncol 7:1630-1636, 1989
19. Radford JA, Rohatiner A, Ryder WD, et al: ChlVPP/EVA Hybrid chemotherapy for Hodgkin's disease: A seven drug, etoposide containing regimen with a low incidence of secondary AML/MDS-Updated results after prolonged follow-up of two consecutive clinical trials involving 701 patients. Ann Oncol 13:s63, 2002
20. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002